Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant.

ABSTRACT:

Background

The advent of direct-acting antiviral therapy for Hepatitis C (HCV) has made using HCV-viremic donors a viable strategy to address the donor shortage in heart transplantation. We employed a large-scale simulation to evaluate the impact and cost-effectiveness of using HCV-viremic donors for heart transplant.

Methods

We simulated detailed histories from time of listing until death for the real-world cohort of all adults listed for heart transplant in the United States from July 2014 to June 2019 (n = 19,346). This population was imputed using historical data and captures "real-world" heterogeneity in geographic and clinical characteristics. We estimated the impact of an intervention in which all candidates accept HCV+ potential donors (n = 472) on transplant volume,

SUBMITTER: Wayda B 

PROVIDER: S-EPMC8973316 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature